Neqlofol (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Beclometasone dipropionate activates glucocorticoid receptors in airway cells, suppressing the production of inflammatory mediators and cytokines. This reduces airway inflammation, edema, and mucus production, helping to keep the airways open and less reactive.

The specific dose and dosing schedule of Neqlofol are determined by the prescribing healthcare professional based on the patient’s age, disease severity, and response to therapy. Patients should follow the prescriber’s instructions and the device’s dosing guide.

Safety data for Neqlofol in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To request Neqlofol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Neqlofol combines beclometasone, a potent inhaled corticosteroid, with formoterol, a fast‑acting long‑acting β2‑agonist. Compared with single‑component inhalers, this combination offers both anti‑inflammatory and bronchodilator effects in one device, potentially improving adherence and providing quicker symptom relief than some other corticosteroid/LABA pairs.

Neqlofol should be stored below 30 °C, in its original packaging, protected from moisture and direct heat. The inhaler should be kept upright, and the mouthpiece should be cleaned regularly according to the manufacturer’s instructions to maintain device performance.

Neqlofol is delivered via a press‑urized metered‑dose inhaler. The patient should exhale fully, place the mouthpiece in the mouth, seal lips around it, and inhale slowly and deeply while actuating the device. A spacer may be used to reduce oropharyngeal deposition, and the patient should rinse the mouth after use.

Serious adverse events include paradoxical bronchospasm, adrenal suppression, significant tachycardia or arrhythmias, severe allergic reactions such as anaphylaxis, and pneumonia in COPD patients. Any sudden worsening of breathing, unexplained fatigue, or signs of infection should prompt immediate medical evaluation.

Neqlofol is contraindicated in patients with a known hypersensitivity to beclometasone, formoterol, or any excipients in the inhaler. It should also be avoided in individuals who have experienced a severe allergic reaction to other inhaled corticosteroids or long‑acting β2‑agonists.